CVRx | Barostim

  Today we announced our third quarter results and provided a business outlook for the rest of 2024. We are pleased to share these milestones: -Active US implanting centers increased 31% over prior year Q3 -US HF revenue increased 30% over prior year Q3 -Increased worldwide revenue 27% over prior year Q3 -CMS reassigned Barostim to a higher paying MS-DRG for inpatient procedures -AMA CPT® Editorial Panel accepted new CPT Category I codes for Barostim -New quality of life data was published in JACC: Heart Failure Learn more: https://barost.im/3AgAnGu

This past weekend, our team was happy to support the Kansas and Missouri ACC Scientific Session. Thanks to the attendees who stopped by to learn about #Barostim for the improvement of #heartfailure symptoms!

We're honored to support Drs. Eric Trestman and Harsh Patel and the team at Townsen Memorial Hospital on their first #Barostim implant. Their patients now have access to a novel device therapy for #heartfailure symptom improvement beyond GDMT alone.

JOIN US TODAY for a webinar where two leading heart failure specialists and an HF program leader will share their experience, perspective, and outcomes incorporating Barostim into their comprehensive advanced heart failure programs. Register now! https://ow.ly/mJyR50TSyqM

Tune in tomorrow at 2 pm ET to hear leading heart failure specialists (Peter Eckman, MD and Pujan Patel, MD) and a HF program leader (Gordon B. Wesley DBA, FACHE) share their experience incorporating #Barostim into their comprehensive advanced HF programs. Bonnie Handke, RN, MBA will dig into the reimbursement and payment landscape that’s helping programs grow and thrive. Register here: https://lnkd.in/gD_fhn-d

We're proud to partner with Drs. Jeko Madjarov and John Rommel and the team at Novant Health New Hanover Regional Medical Center on their first #Barostim implant. Their patients now have access to a novel device therapy to improve #heartfailure symptoms.

Reimbursement News: Today the American Medical Association CPT Editorial Panel accepted new CPT Category I codes for #Barostim.   “The Category I code designation represents an important milestone for the company and is a testament to the increased adoption, safety, and effectiveness of Barostim as an important option for patients suffering from the debilitating symptoms of heart failure. We greatly appreciate the support and guidance that the Society of Vascular Surgery and American College of Cardiology provided throughout this process,” said Kevin Hykes, President and CEO of CVRx.   The codes are expected to be implemented on January 1, 2026.   Read the full press release: https://barost.im/3Agzdum

Join Cardiovascular Business for a webinar on Oct. 24 where two leading heart failure specialists (Peter Eckman, MD and Pujan Patel, MD) and a HF program leader (Gordon B. Wesley DBA, FACHE) share their experience, perspective, and outcomes incorporating #Barostim into their comprehensive advanced HF programs. Bonnie Handke, RN, MBA will dig into the reimbursement and payment landscape that’s helping programs grow and thrive. Register here: https://lnkd.in/gD_fhn-d

We were happy to support the New Cardiovascular Horizons Chicago Meeting this past weekend! Thanks to Dr. Stanislaw Skaluba for presenting on Innovative Device Interventions for #HeartFailure Patients and to the attendees who stopped by our booth to learn more about #Barostim.

In this new CME program, a multidisciplinary faculty - Christina Economides, MD, Brian Howard, MD, and David Kenigsberg, MD, FHRS - reviews the rationale for Barostim therapy, the supporting clinical data, the surgical procedure for the Barostim device, and best practices for optimizing a multidisciplinary approach. This program is CME-accredited medical education developed by ReachMD and Medtelligence and supported by CVRx. Access the program: https://lnkd.in/gfemnqRB